黏蛋白MUC5AC在呼吸系统疾病中的研究进展  

Research progress of mucin MUC5AC in respiratory diseases

作　　者：叶园园 章洪萍 侯润华 张春云[1] 李德富[1] Ye Yuanyuan;Zhang Hongping;Hou Runhua;Zhang Chunyun;Li Defu(Department of Critical Care Medicine,the Fifth Affiliated Hospital of Guangzhou Medical University,Key Laboratory of Bio-targeted Diagnosis and Rehabilitation of Guangdong Universities,Guangzhou 510700,China)

机构地区：[1]广州医科大学附属第五医院重症医学科、广东高校生物靶向诊治与康复重点实验室,广州510700

出　　处：《国际呼吸杂志》2024年第8期978-983,共6页International Journal of Respiration

基　　金：广东省自然科学基金面上项目(2022A1515012504);国家自然科学基金(81900033);广州市校(院)联合资助项目基础与应用基础研究项目(202201020513);广州市医学重点学科(2021-2023)。

摘　　要：气道黏液作为呼吸道抵抗吸入病原体和颗粒物损害的第一道先天防线,其主要固体成分是黏蛋白MUC5AC和MUC5B,其中MUC5AC被认为是最重要的一种。MUC5AC基因过表达是多种呼吸系统疾病的重要特征,包括慢性阻塞性肺疾病、支气管哮喘和囊性纤维化。MUC5AC基因的表达受多个方面的调节,包括转录水平、转录后水平、翻译后生物合成过程和表观遗传水平。本文对其调节机制及在呼吸系统疾病中的研究进展进行综述。Airway mucus serves as the first innate defense of the respiratory tract against inhaled pathogens and invasion of particulate matters.Mucins MUC5AC and MUC5B are the major solid components of airway mucus,especially the former one.Overexpression of the MUC5AC is an important feature in a variety of respiratory diseases,including chronic obstructive pulmonary disease,asthma,and cystic fibrosis.Expression level of MUC5AC is multi-regulated at transcriptional,post-transcriptional,post-translational biosynthetic process and epigenetic levels.This article aims to review the regulatory mechanism and the progress of research on MUC5AC in respiratory diseases.

关 键 词：肺疾病 慢性阻塞性 哮喘 囊性纤维化 MUC5AC 

分 类 号：R56[医药卫生—呼吸系统]